Regeneron Pharmaceuticals, Inc.
NASDAQ:REGN · NASDAQ Global Select
-$5.45 today
Vol 2.04M · Avg 0.91M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:REGN · Revenue to Net Income
Key Ratios
Analysis
$14.9B of revenue converted into $4.4B of net income for the selected period. Gross margin is 84.5% and net margin is 29.7%, showing how much revenue survives after costs and taxes. EPS is $41.04, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.3B +1.0% | $14.2B +8.3% | $13.1B +7.8% | $12.2B -24.3% | $16.1B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $2.1B +6.6% | $2.0B -12.2% | $2.2B +31.6% | $1.7B -37.4% | $2.7B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $12.2B +0.1% | $12.2B +12.5% | $10.9B +3.9% | $10.5B -21.6% | $13.3B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 85.4% -0.8pp | 86.1% +3.2pp | 82.9% -3.1pp | 86.0% +2.9pp | 83.1% | 9.8% | 28.9% | 38.3% |
| Research & Development | $5.9B +11.8% | $5.2B +31.3% | $4.0B +30.5% | $3.1B +16.6% | $2.6B | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $2.7B -8.6% | $3.0B +16.3% | $2.5B +20.0% | $2.1B +15.9% | $1.8B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $8.7B +5.1% | $8.2B +26.3% | $6.5B +28.4% | $5.1B +15.5% | $4.4B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $543.7M +12.6% | $482.9M +14.7% | $421.0M +23.3% | $341.4M +19.3% | $286.2M | $374.2M | $1.2B | $631.8M |
| EBITDA | $5.8B +9.4% | $5.3B +13.3% | $4.7B -10.8% | $5.3B -45.6% | $9.7B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 40.6% +3.1pp | 37.4% +1.7pp | 35.8% -7.4pp | 43.2% -17.0pp | 60.2% | 5.6% | 46.3% | 42.0% |
| Operating Income | $3.6B -10.3% | $4.0B -8.2% | $4.3B -19.3% | $5.4B -39.8% | $8.9B | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 24.9% -3.2pp | 28.1% -5.1pp | 33.2% -11.1pp | 44.2% -11.4pp | 55.7% | 16.6% | 24.1% | 22.0% |
| Interest Income | $716.8M +0.8% | $711.4M +43.5% | $495.9M +209.7% | $160.1M | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $43.8M -20.7% | $55.2M -24.4% | $73.0M +22.9% | $59.4M +3.7% | $57.3M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $1.7B +109.4% | $789.2M +628.6% | -$149.3M +71.7% | -$526.8M -239.0% | $379.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $5.2B +9.4% | $4.8B +13.8% | $4.2B -13.6% | $4.9B -47.9% | $9.3B | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 36.5% +2.8pp | 33.7% +1.6pp | 32.0% -7.9pp | 39.9% -18.1pp | 58.0% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $725.8M +97.6% | $367.3M +49.5% | $245.7M -52.8% | $520.4M -58.4% | $1.3B | $1.3B | -$1.6B | $745.2M |
| Net Income | $4.5B +2.1% | $4.4B +11.6% | $4.0B -8.9% | $4.3B -46.3% | $8.1B | $4.9B | $4.8B | $4.7B |
| Net Margin | 31.4% +0.3pp | 31.1% +0.9pp | 30.1% -5.5pp | 35.6% -14.6pp | 50.2% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $43 +5.3% | $41 +10.4% | $37 -8.5% | $41 -47.0% | $76 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $41 +8.2% | $38 +10.3% | $35 -9.0% | $38 -46.9% | $72 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $104.6M -3.1% | $107.9M +1.1% | $106.7M -0.4% | $107.1M +1.3% | $105.7M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $108.6M -5.6% | $115.1M +1.2% | $113.7M +0.2% | $113.5M +1.2% | $112.2M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Elevance Health Inc.
NYSE:ELV
$84.08B
Cigna Corporation
NYSE:CI
$74.10B
argenx SE
NASDAQ:ARGX
$54.43B
Cencora, Inc.
NYSE:COR
$52.62B
IDEXX Laboratories, Inc.
NASDAQ:IDXX
$44.03B
Alnylam Pharmaceuticals, Inc.
NASDAQ:ALNY
$36.95B
Zoetis Inc.
NYSE:ZTS
$32.88B
United Therapeutics Corporation
NASDAQ:UTHR
$22.96B
Incyte Corporation
NASDAQ:INCY
$19.42B
Genmab A/S
NASDAQ:GMAB
$15.55B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does REGN generate?
Regeneron Pharmaceuticals, Inc. (REGN) reported $14.34B of revenue in fiscal 2025.
Is REGN profitable?
Regeneron Pharmaceuticals, Inc. (REGN) reported $4.50B of net income, with a net margin of 31.4%.
Explore More
Continue the stock analysis
Jump to another research area for this company.